In this video, Howard S. Hochester, MD, discusses the COMMIT study comparing the anti-PD1 drug atezolizumab with atezolizumab combined with FOLFOX chemotherapy presented as part of a poster session at ASCO Annual Meeting.
«When we started this study, it wasn’t known if it was better to give chemotherapy or immunotherapy, an anti-PD1 drug — in this study it was atezolizumab — or to give the combination,» Hochester, associate director for clinical research and director of GI Oncology at Rutgers Cancer Institute, said.
The study evaluated three arms, including chemotherapy alone;